trial

Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen

NCTId NCT01555814
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 56 (actual)
Sponsored by Birte Glenthoj
Primary completion 2016-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
56 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2011-05
Primary completion
2016-07
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
Amisulpride

Sponsors

Birte GlenthojLead Sponsor
Glostrup University Hospital, CopenhagenCollaborator
Rigshospitalet, DenmarkCollaborator
Institute of Psychiatry, LondonCollaborator
UMC UtrechtCollaborator
Copenhagen Hospital CorporationCollaborator

Investigators

1
Birte Glenthoj, MD, DMSc.Principal Investigator

Sites

1 total
Glostrup Municipality, Denmark

Facts & assertions

4 sourced
Enrollment
56
Phase
NA
Primary Completion Date
2016-07
Status
COMPLETED
relationships
The graph out of here
drug
Amisulpride
drug
lead_sponsor
Birte Glenthoj
company
collaborator
Glostrup University Hospital, Copenhagen
company
Rigshospitalet, Denmark
company
indication
Schizophreniform Disorder
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Birte Glenthoj, MD, DMSc.
person